Cytochrome P450 family 1 subfamily A member 2, Cytochrome P450 family 2 subfamily A member 6, and Cytochrome P450 family 2 subfamily C member 19 (CYP1A2, CYP2A6, CYP2C19)

CYP1A2, CYP2A6, and CYP2C19 are critical enzymes within the Cytochrome P450 (CYP) superfamily, primarily localized in the hepatic endoplasmic reticulum where they facilitate the Phase I oxidative metabolism of a vast array of clinical drugs and xenobiotics [1, 10, 16]. CYP1A2 is prominently involved in the metabolism of polycyclic aromatic hydrocarbons and therapeutic agents like caffeine, theophylline, and clozapine, and its activity is significantly induced by environmental factors such as cigarette smoking [11, 22]. CYP2A6 is the primary enzyme responsible for the metabolic clearance of nicotine and serves as a major determinant of smoking behavior and tobacco-related lung cancer risk [10, 14, 19]. CYP2C19 is essential for the metabolic activation of the antiplatelet prodrug clopidogrel, as well as the clearance of proton pump inhibitors and various antidepressants [4, 15, 21]. Genetic polymorphisms in these enzymes are highly prevalent across different populations, leading to distinct poor, intermediate, and ultra-rapid metabolizer phenotypes that can result in therapeutic failure or severe adverse drug reactions [2, 18, 20]. These enzymes are also common sites for drug-drug interactions, where inhibition or induction by co-administered medications can dramatically alter the plasma concentrations and safety profiles of substrate drugs [17, 23]. For biotech and pharmaceutical analysts, these enzymes are paramount in pharmacokinetics, safety assessment, and the development of personalized dosing strategies based on patient genotype [21, 25].

Other names

P3-450CP12CYPIA2CPA6CYP2A3CYPIIA6CPCJCYPIIC19P450C2CP450IIC19

These enzymes function as heme-thiolate monooxygenases that catalyze the Phase I oxidative metabolism of drugs and xenobiotics by inserting one atom of molecular oxygen into the substrate, with the second oxygen atom reduced to water using electrons donated by NADPH via cytochrome P450 reductase [1, 3, 11, 23].